Grifols

Grifols, a multinational Catalan biopharmaceutical company specializing in plasma-derived therapies, is currently in the news due to its plan to launch an Initial Public Offering (IPO) of a minority stake in its Biopharma business in the United States. This division is a major revenue generator for Grifols. The IPO aims to reduce the company's debt, bolster its balance sheet, and fund future investments and growth. This move comes after a period of market challenges, including scrutiny from the activist fund Gotham, which had negatively impacted Grifols' stock performance. News of the IPO has led to a surge in Grifols' share price, although volatility remains. Grifols' work is relevant to rare disease treatment, as plasma is key for therapies for patients with rare diseases.